We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarkers Evaluated in Children with Community-Acquired Pneumonia

By LabMedica International staff writers
Posted on 01 Jun 2020
Print article
Image: The C-reactive protein (CRP) test was one of the biomarkers evaluated in children with community-acquired pneumonia (Photo courtesy of Healsens Digital Preventive Care).
Image: The C-reactive protein (CRP) test was one of the biomarkers evaluated in children with community-acquired pneumonia (Photo courtesy of Healsens Digital Preventive Care).
Community acquired pneumonia (CAP) is one of the most common conditions treated by pediatricians, yet predicting disease severity and prognosis is often difficult at the initial presentation.

Previous studies on adults indicate that the biomarkers C-reactive protein (CRP), white blood cell (WBC) count, absolute neutrophil count (ANC), and procalcitonin may be associated with disease severity. Whether the same was true in children aged three months to 18 years with suspected CAP who presented to the emergency department (ED) has been investigated.

Pediatricians at the Feinberg School of Medicine (Chicago, IL, USA) and their colleagues performed a prospective cohort study of 477 children 3 months to 18 years of age (mean age 5.6 years, 52.6% male, 67% white) with CAP in the emergency department. The primary outcome was disease severity: mild (discharged from the hospital), mild-moderate (hospitalized but not moderate-severe or severe), moderate-severe (e.g., hospitalized with receipt of intravenous fluids, supplemental oxygen, complicated pneumonia), and severe (e.g., intensive care, vasoactive infusions, chest drainage, severe sepsis). Outcomes were examined within the cohort with suspected CAP and in a subset with radiographic CAP.

The scientists reported that there were no statistical differences in median WBC count, CRP level, ANC, or procalcitonin level across four different categories of disease severity. However, when specific outcomes were examined, CRP and procalcitonin levels were higher in those developing complicated pneumonia requiring chest tube placement and sepsis requiring vasoactive medications. Additionally, all biomarkers had high negative predictive values (NPV) in differentiating severe from non-severe disease and may therefore be useful in ruling out severe outcomes.

In analyses adjusted for age, antibiotic use, fever duration, and viral pathogen detection, CRP was associated with moderate-severe disease (odds ratio 1.12). CRP and procalcitonin revealed good discrimination of children with empyema requiring chest drainage (AUC: 0.83) and sepsis with vasoactive infusions (CRP AUC: 0.74; procalcitonin AUC: 0.78), although prevalence of these outcomes was low.

The authors concluded that WBC count, ANC, CRP, and procalcitonin are generally not useful to discriminate non-severe from severe disease in children with CAP, although CRP and procalcitonin may have some utility in predicting the most severe outcomes. The study was published in the May, 2020 issue of the journal Pediatrics.

Related Links:
Feinberg School of Medicine

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Macrophages infected with mycobacterium tuberculosis (Photo courtesy of MIT)

New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests

Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more